Genomic Valley, a company in the Biotechnology industry, reported revenue of ₹0.04 crore and net profit of ₹0.01 crore for the June 2026 quarter.
Genomic Valley (BSE: GVBL) closed at ₹44.75 on 20 Nov 2026, up 47.4% over the past year. Its market capitalisation is ₹14 crore.
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.